Transcutaneous Electrical Acustimulation Improves Irritable Bowel Syndrome With Constipation by Accelerating Colon Transit and Reducing Rectal Sensation Using Autonomic Mechanisms
- PMID: 35973183
- DOI: 10.14309/ajg.0000000000001882
Transcutaneous Electrical Acustimulation Improves Irritable Bowel Syndrome With Constipation by Accelerating Colon Transit and Reducing Rectal Sensation Using Autonomic Mechanisms
Abstract
Introduction: Slow colon transit and visceral hypersensitivity are recognized as major pathophysiological mechanisms in irritable bowel syndrome with constipation (IBS-C). However, there is a lack of therapies targeting both abdominal pain and colonic motility. This study was designed to investigate the long-term effects and possible mechanisms of transcutaneous electrical acustimulation (TEA) in patients with IBS-C.
Methods: Fifty-two patients with IBS-C were randomized into 2 groups: daily TEA for 4 weeks (n = 26) and daily sham-TEA for 4 weeks (n = 26). The number of complete spontaneous bowel movements per week (CSBMs/week, primary outcome), Irritable Bowel Syndrome Severity Scoring System, Patient Assessment of Constipation Quality of Life, visual analog scale (VAS) pain score, colonic transit time, and anorectal physiology were evaluated before treatment and at the end of the treatment. Colonic transit was assessed with radiopaque markers. Electrocardiograms were recorded for assessing autonomic functions.
Results: (i) TEA improved constipation and abdominal pain. After the treatment, the number of CSBMs/week during the last week in the TEA group was higher than that in the sham-TEA group (3.5 ± 1.6 vs 2.3 ± 0.6, P = 0.002). Similar effects were also noted in the visual analog scale pain score ( P = 0.002) and Irritable Bowel Syndrome Severity Scoring System score ( P = 0.025). In addition, there was a significant improvement in the quality of life of patients with constipation. The Patient Assessment of Constipation Quality of Life total score was significantly decreased in the TEA group ( P = 0.004). (ii) Compared with sham-TEA, TEA improved colon transit ( P = 0.002) and increased the threshold of rectal sensation (desire to defecate, P = 0.004; maximum tolerability, P < 0.001). (iii) TEA increased vagal activity, compared with sham-TEA ( P < 0.05); at the end of the treatment, the vagal activity was significantly correlated with colon transit and the CSBMs/week.
Discussion: TEA improves constipation and symptoms of IBS by accelerating colon transit and reducing rectal sensation, possibly mediated by using the autonomic mechanisms.
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Similar articles
-
Ameliorating effects and mechanisms of transcutaneous auricular vagal nerve stimulation on abdominal pain and constipation.JCI Insight. 2021 Jul 22;6(14):e150052. doi: 10.1172/jci.insight.150052. JCI Insight. 2021. PMID: 34138761 Free PMC article. Clinical Trial.
-
The impact of transcutaneous electrical acustimulation (TEA) on rectal distension-induced pain in patients with irritable bowel syndrome (IBS)-A study to determine the optimal TEA delivery modalities and effects on rectal sensation and autonomic function.Neurogastroenterol Motil. 2024 Jul;36(7):e14799. doi: 10.1111/nmo.14799. Epub 2024 Apr 26. Neurogastroenterol Motil. 2024. PMID: 38671591 Clinical Trial.
-
Transcutaneous Electrical Acustimulation Improves Constipation Symptoms and Accelerates Colonic Transit in Patients With Slow Transit Constipation Through Autonomic Mechanism.Neuromodulation. 2024 Feb;27(2):382-391. doi: 10.1016/j.neurom.2023.11.005. Epub 2023 Dec 21. Neuromodulation. 2024. PMID: 38127047 Clinical Trial.
-
Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.Clin Gastroenterol Hepatol. 2013 Sep;11(9):1084-1092.e3; quiz e68. doi: 10.1016/j.cgh.2013.04.032. Epub 2013 May 2. Clin Gastroenterol Hepatol. 2013. PMID: 23644388
-
A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.Curr Med Res Opin. 2013 Feb;29(2):149-60. doi: 10.1185/03007995.2012.754743. Epub 2012 Dec 20. Curr Med Res Opin. 2013. PMID: 23198977 Review.
Cited by
-
Similarities between Ashi acupoints and myofascial trigger points: Exploring the relationship between body surface treatment points.Front Neurosci. 2022 Nov 2;16:947884. doi: 10.3389/fnins.2022.947884. eCollection 2022. Front Neurosci. 2022. PMID: 36408408 Free PMC article.
-
Analysis of Electroacupuncture Parameters for Irritable Bowel Syndrome: A Data Mining Approach.J Pain Res. 2025 Apr 23;18:2175-2189. doi: 10.2147/JPR.S483750. eCollection 2025. J Pain Res. 2025. PMID: 40290613 Free PMC article.
-
Non-invasive neuromodulation: an emerging intervention for visceral pain in gastrointestinal disorders.Bioelectron Med. 2023 Nov 22;9(1):27. doi: 10.1186/s42234-023-00130-5. Bioelectron Med. 2023. PMID: 37990288 Free PMC article. Review.
-
The effect of acupuncture on quality of life in patients with irritable bowel syndrome: A systematic review and meta-analysis.PLoS One. 2025 Feb 13;20(2):e0314678. doi: 10.1371/journal.pone.0314678. eCollection 2025. PLoS One. 2025. PMID: 39946356 Free PMC article.
-
Neuromodulation for functional upper gastrointestinal diseases.Gut Microbiota Integr Wellness. 2023;1:10.54844/gmiw.2022.0087. doi: 10.54844/gmiw.2022.0087. Epub 2023 Apr 28. Gut Microbiota Integr Wellness. 2023. PMID: 38406297 Free PMC article.
References
-
- Camilleri M. Diagnosis and treatment of irritable bowel syndrome: A review. JAMA 2021;325:865–77.
-
- Chey WD. Irritable bowel syndrome. Gastroenterol Clin North Am 2021;50:xv–xvi.
-
- Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut 2021;70:1214–40.
-
- Tang HY, Jiang AJ, Wang XY, et al. Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: A narrative review. Ann Transl Med 2021;9:1187.
-
- Rabitti S, Giovanardi CM, Colussi D. Acupuncture and related therapies for the treatment of gastrointestinal diseases. J Clin Gastroenterol 2021;55:207–17.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources